|Articles|June 1, 2004
Managing risk of pregnancy
The teratogenicity of isotretinoin has been known since isotretinoin was first introduced for acne treatment. Because of this, Patricia Farris, M.D., a dermatologist based in Metairie, La., not only insists on adequate birth control use but adds that the patient must be open to the possibility that if her birth control fails that she would terminate the pregnancy.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5













